Since we have proven that the reduced CR1 expression does not influence the physiological function of the receptor, we assume that CR1 may be considered as a potential therapeutical target in certain “B cell-driven” autoimmune diseases, like SLE and RA, to decrease activation of autoreactive B cells. This evidence concerns the gene CR1 and systemic lupus erythematosus.